<DOC>
	<DOC>NCT00140218</DOC>
	<brief_summary>The hypothesis of this study is that treatment with R(+) pramipexole at 30 mg/day will alter the slope of decline in ALS functional rating scale over the course of 6 months. ALS patients at an early stage of disease will be observed for 3 months after enrollment and then treated with drug for 6 months.</brief_summary>
	<brief_title>R(+) Pramipexole in Early Amyotrophic Lateral Sclerosis</brief_title>
	<detailed_description>This is a futility design Phase II study using ALS-FRSr as the primary variable to monitor progression of disease in patients with early ALS. The drug to be tested is R(+) pramipexole, an antioxidant that concentrates into brain and mitochondria. R(+)PPX will be administered at 30 mg/day over 6 months, following a 3 month lead-in period without drug therapy. For purposes of this study, futility is defined as failure to decrease the slope of ALS-FRSr decline by less than 40%.</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>established diagnosis of ALS FVC&gt;60% of predicted not being ventilated no difficulty swallowing ambulatory (can use assistance devices) ALS duration &gt;3 years advanced ALS with survival predicted &lt;6 months dementia (MMSE&lt;22) prior exposure to R(+) pramipexole orthostatic hypotension &gt;30 mmHg history of psychosis or hallucinations abnormal baseline safety lab values</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>amyotrophic lateral sclerosis</keyword>
	<keyword>pramipexole</keyword>
	<keyword>oxidative stress</keyword>
	<keyword>neuroprotection</keyword>
</DOC>